Just as it followed other sectors into CRM, the pharma industry must find entry points into the online patient conversation. Gil Bashe explores some of the issues, hurdles and opportunities of Web 2.0
Although feelings in the mainstream drug industry will be mixed, it’s time to end the secrecy that surrounds the FDA’s decision-making on approving drugs.